Kiadis Pharma Terug naar discussie overzicht

KIadis naar de €15,00 in november

1. Windkracht 29 november 2017 21:02

   auteur info

   • Windkracht

     Lid sinds: 18 jan 2008

     Laatste bezoek: 15 nov 2024

   • Aanbevelingen

     Ontvangen: 261

     Gegeven: 78

   •    Aantal posts: 2.319

   Mooi bericht van dat koersdoel van eur 19.- met het advies kopen!
   Ik zie dat het bericht nabeurs 17.55 gekomen is. Zou het wat met de koers doen morgen.....vast niet.
2. [verwijderd] 29 november 2017 21:31

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   idd leuk bericht... als de koers nu nog naar het koersdoel wil lopen :)
3. emergo 30 november 2017 08:42

   auteur info

   • emergo

     Lid sinds: 12 jul 2017

     Laatste bezoek: 14 jul 2023

   • Aanbevelingen

     Ontvangen: 211

     Gegeven: 258

   •    Aantal posts: 770

   Denk het niet.Is flutaandeel.Kijk naar afgelopen weken.Kijk naar vanmiddag 17.35 uur.
   Flut.Ongetwijfeld bezig met schitterend produkt maar hebben nog niets en dat vertaalt zich in de koers.
   Sry voor de believers maar ik heb er inmiddels 3 x mijn neus mee gestoten en wil gewoon even frustratie kwijt.
4. Windkracht 30 november 2017 08:47

   auteur info

   • Windkracht

     Lid sinds: 18 jan 2008

     Laatste bezoek: 15 nov 2024

   • Aanbevelingen

     Ontvangen: 261

     Gegeven: 78

   •    Aantal posts: 2.319

   Dat mag! Het lastige met biotech aandelen is dat de eventuele enorme winst in een paar dagen wordt gemaakt en de rest van de tijd ligt de koers stil. Je weet alleen nooit wanneer de jump is.
5. [verwijderd] 30 november 2017 08:55

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Er zullen de komende 12 maanden slechts een beperkt aantal persberichten naar buiten worden gebracht, zoals mogelijk:
   
   - updates klinische studies (december 2017, en wellicht ook nog in 2018)
   - voortgang EMA goedkeuring / in best case resulterend in voorlopige goedkeuring (maart / H2 2018)
   - voortgang FDA traject (onbekend)
   - meldingen over samenwerkingen / partnership (onbekend)
   - wetenschappelijke publicaties (onbekend)
   - eventuele emissie (H2 2018)
   
   Een aantal hiervan kunnen grote invloed op de koers hebben.
6. [verwijderd] 30 november 2017 09:14

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   geen mogelijkheid om te kopen blijkbaar? of heb ik het verkeerd voor?
7. [verwijderd] 30 november 2017 09:16

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   je kan niet kopen wanneer je wilt en niet verkopen wanneer je wilt ... bizar
8. Windkracht 30 november 2017 09:19

   auteur info

   • Windkracht

     Lid sinds: 18 jan 2008

     Laatste bezoek: 15 nov 2024

   • Aanbevelingen

     Ontvangen: 261

     Gegeven: 78

   •    Aantal posts: 2.319

   Je wordt gedwongen uit de laat te kopen of hoger. De koers wordt weer netjes vastgezet;-)
9. Windkracht 30 november 2017 09:23

   auteur info

   • Windkracht

     Lid sinds: 18 jan 2008

     Laatste bezoek: 15 nov 2024

   • Aanbevelingen

     Ontvangen: 261

     Gegeven: 78

   •    Aantal posts: 2.319

   Heel apart inderdaad wat er gebeurt nu!!!
   Heb een order ingelegd op 7,865 en die blijft gewoon open staan terwijl gekocht wordt op 7,862.
   
   Broekzak/vestzak verkopen. Deze acties ondersteunen m.i. alleen maar de potentie van dit aandeel.
10. Windkracht 30 november 2017 09:42

    auteur info

    • Windkracht

      Lid sinds: 18 jan 2008

      Laatste bezoek: 15 nov 2024

    • Aanbevelingen

      Ontvangen: 261

      Gegeven: 78

    •    Aantal posts: 2.319

    www.letlifehappen.com/car-t-cell-ther...
    
    CAR T-Cell Therapy Is Making Untreatable Cancer Treatable
    In In The News by Barbara JacobyNovember 10, 20170 Comments
    112FacebookTwitterPinterestLinkedIn
    By: Neel V. Patel
    
    From: dailybeast.com
    
    Immunotherapy is one of the buzziest words in medicine. Touted as the future for aggressively fighting—maybe even eliminating—diseases, the idea is to jumpstart the patient’s own immune system into better identifying and attacking diseases that normally escape attack and stealthily conquer the body. Alongside immunotherapy is the emergent ability of scientists to genetically modify cells to act in exact ways.
    
    What if, now, you could combine the reenergizing powers of immunotherapy with the sharp-shooter specificity of gene therapy? Theoretically, you get treatments that have the astounding potential to make those on the verge of death live.
    
    That is, if the treatment doesn’t kill them first.
    
    Straddling this balance is chimeric antigen receptor (CAR) T-cell therapy: a revolutionary cancer treatment where doctors take a patient’s own T-cells (which play a significant role in the body’s cell-mediated immune response), genetically reengineer them so they facilitate a more directed and powerful attack against tumor cells, make millions of copies, and infuse them back into the patient so they kill cancerous cells. CAR T-cells have the unique superpower of being able to recognize specific cancer cells with the CAR molecule on their surfaces, said David Porter, an oncologist and cancer researcher based at the University of Pennsylvania. “It essentially reprograms the T-cell so it can now recognize the cancer cell,” he noted.
    
    It seems to work phenomenally well. The FDA recently approved two new CAR T-cell therapies: Kymriah, for pediatric and young adults up to age 25 suffering from acute lymphoblastic leukemia (ALL); and Yescarta, for adult patients with certain forms of non-Hodgkin lymphoma—cancers that leave patients with few optimistic options. In Phase II clinical trials assessing the effects of the treatments, Kymriah—which Porter helped create—led to complete cancer remission (i.e., no evidence of the disease) in 83 percent of patients; for Yescarta, complete remission was found in 51 percent of patients.
    
    Porter analogizes CARs to velcro: a patient’s own T-cells don’t readily possess the other piece of velcro which will stick to the cancer cell’s velcro. So scientists will change up the T-cell’s genes so they have that velcro. They can now recognize and stick to—and attack—the cancer cells.
    
    “This is really like a living drug,” said Porter. “It grows in the body.” One of the most phenomenal aspects is how effective the therapy is in staving off relapse. Once the malignancy is eliminated, there’s a very good chance it stays gone. James Kochenderfer, a scientist at the National Cancer Institute’s Center for Cancer Research who’s worked on Yescarta, and Porter alike note that patients treated as far as six to seven years ago are still in remission. For those patients who are cured, they no longer need any kind of treatment.
    
    “After a few weeks in the hospital allowing the T-cells to attack the cancer and contending with the side effects, they exit the treatment ecstatic,” said Kochenderfer. “It’s incredible how well they do, and how much we’ve learned.”
    
    But when you take the brakes off the immune system like that, there are potential crashes that threaten to derail the whole thing. A cure for cancer like CAR T-cell therapy is not without its grave safety concerns. Any infection causes the body’s T-cells to activate and release what are called cytokines—signals lead to a rise in body temperature and create other symptoms of illness that are ostensibly meant to help fight off infection. “It’s the same thing when the immune system is fighting cancer,” said Kochenderfer. “Except it’s more intense.”
    
    Trials of Yescarta and Kymriah reported some patients experiencing what’s called a cytokine release syndrome (CRS). “It’s like having a really, really severe flu-like syndrome,” said Porter. Fevers can reach a scorching 105 degrees Fahrenheit, create muscle and joint aches, and induce nausea and diarrhea. As CRS progresses, it can lead to dangerously low blood pressure, and life-threatening respiratory problems. Patients with advanced stages of leukemia who are undergoing CAR T-cell therapy are particularly vulnerable to CRS reactions.
    
    But there is a way to mitigate CRS: an immunosuppressive medication called Tocilizumab (normally prescribed for rheumatoid arthritis) can block a protein associated with CRS, and shut off the syndrome in practically an hour or two. “It works most of the time,” said Porter, “though I will note it doesn’t work in everybody.” Researchers are still working on tweaking CAR T-cell therapy—perhaps through the dosage, or the product itself—so it won’t lead to a CRS reaction.
    
    Kochenderfer emphasizes that one of the most exciting things about this field is the ability to genetically modify the cells in any which way. “In my lab, we’ve made hundreds of different CARs, most of which don’t get into clinical trials. But we can easily change the DNA to change what the CAR can do.” Kochenderfer and his team have already developed a CAR T-cell which produces less cytokine and are currently testing whether it diminishes the chances of CRS reactions in patients. When it comes to genetic engineering, there are endless ways to find a solution—it’s just a matter of proving one works.
    
    There are two adjacent issues to safety that CAR T-cell therapy advocates will also need to address as the treatment expands. In a recent Health Affairs article responding to the FDA’s approval of Kymriah, Mildred Solomon, the president of the Hastings Center, and her colleagues argue that problems related to limited patient access and high cost regarding Kymriah (and Yescarta by extension) need resolution.
    
    “In both cases, you have what appears to be a highly effective, potential breakthrough treatment,” said Solomon. “They both engender a great deal of excitement about their efficacy”—obtaining FDA approval through expedited pathways. That rapid approval means the treatments need closer monitoring than usual, as well as policy solutions that don’t leave desperate cancer patients out in the cold.
    
    None of this detracts from what a mind-blowing success CAR T-cell therapy has been so far. “These kinds of breakthroughs don’t happen that often in medicine and oncology,” said Porter. “Many of these patients that we’ve treated have run out of other treatment options. Many of them have now been cured of incurable cancers. That borders on miraculous.”
11. [verwijderd] 30 november 2017 09:49

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    NEVDK schreef op 30 november 2017 09:16:

    je kan niet kopen wanneer je wilt en niet verkopen wanneer je wilt ... bizar
    

    Dit is geen aandeel om in te gaan zitten handelen. Bied en laat liggen vaak ver uiteen. Het is een aandeel om een bescheiden positie op de plank te leggen?
12. Windkracht 30 november 2017 09:52

    auteur info

    • Windkracht

      Lid sinds: 18 jan 2008

      Laatste bezoek: 15 nov 2024

    • Aanbevelingen

      Ontvangen: 261

      Gegeven: 78

    •    Aantal posts: 2.319

    CAR T-Cell Therapy Brings New Hope to Cancer Patients at Stanford Health Care
    11.29.2017
    
    
    Select patients with a certain type of blood cancer now have access to CAR T-cell therapy at Stanford.
    Using a revolutionary new treatment option, Stanford Health Care is now treating certain blood cancers in patients who have failed to improve with chemotherapy, radiation therapy, or stem cell transplant.
    
    Called CAR T-cell therapy, the treatment involves removing immune cells from the patient’s blood, engineering them in a laboratory to improve their cancer-fighting power, then reinfusing them into the patient. The technique is giving hope to people who had been told they were running out of options.
    “It’s exceeding anything I could ever have imagined two years ago,” said David Miklos, MD, PhD, associate professor of medicine at the Stanford University School of Medicine and CAR T-cell therapy expert at Stanford Health Care. “We hijack the patient’s T cells, making a chimeric molecule.”
    Just last month, a new CAR T-cell therapy was approved by the FDA and is now available to select patients with a certain type of hematologic cancer. Stanford Health Care is the only Northern California health system to offer the treatment.
    CAR T-cell therapy, a form of immunotherapy, is a relatively new weapon against cancer. Physicians have known that our immune systems protect us against cancer, but until recently didn’t know how to employ that knowledge. With CAR T-cell therapy, clinicians remove T cells, a kind of white blood cell, from the patient. In a laboratory, they then manipulate the cells with a virus that causes them to produce chimeric antigen receptors, or CARs, which in turn attack the tumor cells.
    “We supercharge the immune system,” Miklos said, adding that the engineered cells stay in the body, fighting cancer “potentially forever.”
    Meanwhile, the patient undergoes chemotherapy to reduce the white blood cell count, which encourages the T cells, once reinfused, to multiply. Nine days after the T cells are removed, the patient receives the infusion. Within a week, the engineered cells increase from 2 million to 20 billion and begin attacking the cancer.
    During the infusion and for several days afterward, patients stay in the hospital so they can be monitored for side effects. Most patients experience what feels like a severe flu — a sign that their immune systems are revving up. Some also develop neurotoxicity, which can affect mental functioning. To treat these conditions, physicians slow down the expansion of the CAR T cells.
    Physicians are currently using CAR T-cell therapy to treat diffuse large B-cell lymphoma and acute lymphoblastic leukemia. Miklos said they hope to treat other forms of cancer, eventually even solid tumors such as those found in breast and lung cancer, in the near future.
    Only patients who have failed to improve after traditional cancer treatments are receiving the therapy for now, but Miklos said the goal is to find treatments that can replace chemotherapy. “Imagine that this is the beginning of no longer depending on chemo for treating patients,” he said. “It’s a game changer.”
13. [verwijderd] 30 november 2017 10:23

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Chiddix schreef op 30 november 2017 09:49:

    [...]
    
    Dit is geen aandeel om in te gaan zitten handelen. Bied en laat liggen vaak ver uiteen. Het is een aandeel om een bescheiden positie op de plank te leggen?
    

    Zit er niet in voor KT. 40% van mijn port. Ik geef het aandeel tot juni-juli volgend jaar en dan alles weg. Dan te gevaarlijk voor verdere verwatering.
    Ik wou een klein stuk verkopen om in een ander biotech aandeel mijn gemidd te verlagen...
14. [verwijderd] 30 november 2017 11:28

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    NEVDK schreef op 30 november 2017 10:23:

    [...]
    
    Zit er niet in voor KT. 40% van mijn port. Ik geef het aandeel tot juni-juli volgend jaar en dan alles weg. Dan te gevaarlijk voor verdere verwatering.
    Ik wou een klein stuk verkopen om in een ander biotech aandeel mijn gemidd te verlagen...
    

    Bij biotechaandelen die met hun medicatie nog niet door de keuring zijn gekomen. moet je een engelengeduld hebben. De keuring is pas over 7-9 maanden. Mocht de EMA het toelaten, duurt het nog wel even voor het middel ingezet wordt(2019). Daarvoor krijg je nog een emissie of bod van farmaceut. Een bod voordat er gekeurd wordt is mogelijk maar daar moet je niet van uitgaan.
15. Sentiment 30 november 2017 12:38

    auteur info

    • Sentiment

      Lid sinds: 13 nov 2003

      Laatste bezoek: 08 nov 2024

    • Aanbevelingen

      Ontvangen: 1191

      Gegeven: 631

    •    Aantal posts: 10.257

    Het kan heel snel gaan, als er flink gekocht gaat worden, staat het zo op 11 euro.
    Daar heb ik nog op gekocht, een paar weken geleden.
16. [verwijderd] 30 november 2017 14:53

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Er gaat echt niemand, zonder dat er een nieuwsmelding is gedaan, 11 euro bieden voor deze aandelen.
    
    Koers staat dichter bij 1,50 dan bij de 15,0.
17. Windkracht 30 november 2017 15:10

    auteur info

    • Windkracht

      Lid sinds: 18 jan 2008

      Laatste bezoek: 15 nov 2024

    • Aanbevelingen

      Ontvangen: 261

      Gegeven: 78

    •    Aantal posts: 2.319

    Na belangrijk nieuws stijgt de koers erg hard en wordt een bieding alleen maar duurder. Ik verwacht eigenlijk ook geen overname, maar Kiadis sluit mi. niets uit, en uiteindelijk is alles te koop!
    Mijn indruk is dat Kiadis internationaal goed bekend is, en de verdere ontwikkelingen m.b.t. Atir101 worden nauwgezet gevolgd. Zodra er ook maar iets aan duidelijkheid komt, wordt het stijgingspotentieel zichtbaar.
    Wat wel herkenbaar is bij aandelen die niet veel fluctueren (zoals Kiadis) er velen negatief lijken te worden. Blijkbaar zitten hier ook korte termijn beleggers, de vraag is of Kiadis dan een goed fonds is, dan moet je wel heel goed kunnen timen, en dat kan helemaal niemand, zelfs Warren Buffet niet.
18. Windkracht 30 november 2017 16:24

    auteur info

    • Windkracht

      Lid sinds: 18 jan 2008

      Laatste bezoek: 15 nov 2024

    • Aanbevelingen

      Ontvangen: 261

      Gegeven: 78

    •    Aantal posts: 2.319

    Incoming Novartis CEO On $475,000 Cancer Therapy: 'No Question That The List Price Raises Eyebrows'
    Michela Tindera , FORBES STAFF
    30 november 2017
    
    www.forbes.com/sites/michelatindera/2...
    Johnny Wolf
    
    Incoming Novartis CEO Vas Narasimhan at the Forbes Healthcare Summit in New York City in November 30, 2017.
    Incoming CEO at Swiss drugmaker Novartis , Vas Narasimhan, said he isn’t interested in following the herd in drug development.
    
    “How do you make smart contrarian bets?” Narasimhan said of his strategy for Novartis Wednesday at the Forbes Healthcare Summit in New York City. Narasimhan, who is the current chief medical officer and head of global drug development at Novartis, will take over for current CEO Joe Jimenez in February.
    
    Novartis’ latest historic bet on cancer therapy Kymriah has made waves throughout the industry. Approved by the Food and Drug Administration in August for use on children with acute lymphoblastic leukemia, it is a novel therapy called a chimeric antigen receptor T-cell, or CAR-T that genetically modifies a patient’s own white blood cells, training them to essentially hunt down and kill tumors.
    
    “We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer,” FDA Commissioner Scott Gottlieb said in a statement in August when Kymriah was approved. “New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses.”
    
    While its implications are vast, the therapy does not come cheap. It’s list price is $475,000 per patient. “There’s no question that the list price raises eyebrows,” Narasimhan said. “We need to price our drugs at a cost-effective level that is acceptable for society,” he expanded. “[Value-based pricing model] is something we have to grapple with. We need to come up with different models for different medicines.”
    
    FORBES reported in October that Novartis has said it's offering insurance companies a value-based pricing structure where it only pays for patients who enter remission within three months.
    
    Johnny Wolf
    Austin Schuetz, one of the first patients to benefit from Novartis' CAR-T treatment, on stage at the Forbes Healthcare Summit with Leukemia & Lymphoma Society president and CEO Louis DeGennaro.
    One of the earliest beneficiaries of this therapy was 10-year-old Austin Schuetz. Shortly before his 3rd birthday he and his parents were given a devastating diagnosis, acute lymphoblastic lymphoma. Over the next few years of his treatment, which included chemotherapy, radiation and a bone marrow transplant, he continued to have relapses until his parents, Kimberly and Jeffrey Schuetz, learned of Novartis' phase one clinical trial for Kymriah. Austin was eligible and he enrolled soon after in 2013.
    
    “We would just kind of wait in the wings, and hope was all we had,” Kimberly Schuetz said at the Summit. Today, Austin, who joined his parents on stage at the Summit, is healthy thanks to the therapy.
    
    “That’s what made me want to join the industry and certainly what motivates me every day,” Narasimhan said. “If we can solve puzzles that biology gives us and change patients lives.”
19. [verwijderd] 30 november 2017 19:26

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Denk dat deze hier ook wel thuis hoort. Komt van het Pharming forum, maar voor Kiadis is dit wereldnieuws :-)
    
    FDA Aims to Expand Early-Approval Program for Promising Drugs
    
    By Anna Edney
    November 30, 2017, 7:28 AM PST
    
    Commissioner proposes approval based on early, small trials
    Scott Gottlieb speaks before House subcommittee on health
    The Food and Drug Administration wants to help patients get faster access to promising cancer treatments.
    
    The agency is preparing proposals that would expand an accelerated-approval program for lifesaving medications, FDA Commissioner Scott Gottlieb told House lawmakers on Thursday.
    
    Drugmakers can seek rapid conditional approval for treatments for cancer or other serious diseases based on evidence that a drug is likely to extend patient survival. Later trials once such a drug is on the market are necessary to prove the survival benefit.
    
    The FDA is now looking at ways to conditionally approve an experimental drug if it shows increased survival in early trials in a small number of patients, Gottlieb said.
    
    Typically, early trials are used to determine how best to craft larger studies and aren’t used for approval. But Gottlieb wants early trials to be used for approval if they show an outsized survival benefit. Any drug cleared based on early-trial data would later have to be proven in larger trials to maintain the benefit.
    
    Gottlieb was speaking before the House Energy and Commerce Committee’s health panel on the FDA’s implementation of the 21st Century Cures Act, a bill passed last year that is meant to accelerate development of new pharmaceuticals. The commissioner has also tried to boost competition and ease drug development in an effort to lower prices.
    
    Earlier this year, the FDA said it would update policies to help drugmakers gain approval of treatments targeting specific gene mutations that can spur tumors. Makers of cancer drugs are increasingly embracing such genetic therapies, compared to the traditional manner of identifying cancers by the affected body part, such as the lung, breast or kidney.
    
    www.bloomberg.com/news/articles/2017-...
20. Windkracht 30 november 2017 20:55

    auteur info

    • Windkracht

      Lid sinds: 18 jan 2008

      Laatste bezoek: 15 nov 2024

    • Aanbevelingen

      Ontvangen: 261

      Gegeven: 78

    •    Aantal posts: 2.319

    De biotechnologie index in de USA heeft het de afgelopen vier weken niet echt goed gedaan, maar vandaag stijgt deze met bijna 2%. Mogelijk kan Kiadis morgen op deze golf mee.